Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma / 生物医学工程学杂志
Journal of Biomedical Engineering
;
(6): 588-592, 2012.
Artigo
em Chinês
| WPRIM
| ID: wpr-271728
ABSTRACT
Traditionally, during the follow-up and in order to receive 131 I therapy, patients with differentiated thyroid carcinoma (DTC) have to withdraw from using thyroid hormone. The hypothyroidism induced by hormone withdrawal can negatively affect the quality-of-life (QOL) of DTC patients. Without the hormone withdrawal, recombinant human thyroid-stimulating hormone-aided management of DTC patients can effectively obviate the consequences of hypothyroidism. This review will focus on the clinical application of recombinant human thyroid-stimulating hormone (rhTSH) in the management of DTC patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Radioterapia
/
Tireoglobulina
/
Hormônios Tireóideos
/
Sangue
/
Neoplasias da Glândula Tireoide
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Tirotropina Alfa
/
Radioisótopos do Iodo
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Biomedical Engineering
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS